Novo Nordisk (NVO) stock vs the S&P 500 and pharmaceutical stocks
As of 20 November 2026, Novo Nordisk (NVO) is trailing both the S&P 500 and pharmaceutical stocks as a group (PPH) over the past three months.
Where Novo Nordisk stands now
As of 20 November 2026, Novo Nordisk had a good month against the S&P 500 after a weaker quarter. One month alone does not make a trend.
Inside its group, NVO lags: it is behind pharmaceutical stocks (PPH) over both the past month and three months. As a group, pharmaceutical stocks are gaining ground on the S&P 500 right now. The group is in transition, so the stock's place inside it matters more than usual.
Novo Nordisk is 5.5% of PPH, so its moves weigh on the fund. The thing to watch is the past month: a turn against the market usually shows there first.
NVO vs the S&P 500: returns
Novo Nordisk and the S&P 500 (SPY) side by side, over each window Zensei tracks.
Prices as of · computed from daily adjusted closes · how we measure
NVO against pharmaceutical stocks, in depth
See the size of the gap between Novo Nordisk and pharmaceutical stocks (PPH) over every window, its momentum and its relative strength, and where it sits among pharmaceutical stocks.
See the full analysisWhich ETFs hold Novo Nordisk?
One fund that Zensei tracks holds NVO, by weight. The fund with the largest weight is its sector on this page.
Novo Nordisk competitors
The largest other holdings of VanEck Pharmaceutical ETF (PPH), with their return over the past month.
Novo Nordisk stock: common questions
Is Novo Nordisk stock beating the S&P 500?
As of 20 November 2026, Novo Nordisk (NVO) is down 3.9% over the past month. The S&P 500 is down 10.3% over the same month. Over three months, the stock is down 19.1% and the S&P 500 is down 9.7%.
Which ETFs hold Novo Nordisk?
As of 20 November 2026, one fund that Zensei tracks holds NVO. Its largest weight is in VanEck Pharmaceutical ETF (PPH), at 5.5%.
Who are Novo Nordisk's competitors?
As of 20 November 2026, the largest other holdings of VanEck Pharmaceutical ETF (PPH) are Eli Lilly (LLY), Merck & Co Inc (MRK), Pfizer (PFE), Mckesson Corp (MCK), Bristol-Myers Squibb Co (BMY). These are the stocks Novo Nordisk sits next to among pharmaceutical stocks.
Is Novo Nordisk doing better than other pharmaceutical stocks?
As of 20 November 2026, Novo Nordisk (NVO) is behind pharmaceutical stocks as a group (PPH) over the past three months. Zensei Edge shows the size of the gap, its momentum and its relative strength.
Recent changes
- ·Among the weakest → trailing the market and pharmaceutical stocks
- ·Trailing the market and pharmaceutical stocks → among the weakest
- ·Among the weakest → trailing the market and pharmaceutical stocks
- ·First tracked: among the weakest
Track Novo Nordisk against pharmaceutical stocks and the market
Zensei Edge maps 100+ sectors and themes against the S&P 500, with each stock inside them measured against its group.